



Universiteit
Leiden
The Netherlands

Development of stealth transgenes for gene therapy : evaluation of cis-acting inhibitors of antigen presentation

Raamsman-Ossevoort, M.

Citation

Raamsman-Ossevoort, M. (2006, February 12). *Development of stealth transgenes for gene therapy : evaluation of cis-acting inhibitors of antigen presentation*. Retrieved from <https://hdl.handle.net/1887/4365>

Version: Corrected Publisher's Version

License: [Licence agreement concerning inclusion of doctoral thesis in the Institutional Repository of the University of Leiden](#)

Downloaded from: <https://hdl.handle.net/1887/4365>

Note: To cite this publication please use the final published version (if applicable).

Chapter 1

Introduction

Part 3

References

Part 3

References

- Aarnoudse, C. A., van den Doel, P. B., Heemskerk, B., and Schrier, P. I. (1999). Interleukin-2-induced, melanoma-specific T cells recognize CAMEL, an unexpected translation product of LAGE-1. *Int.J.Cancer* **82**, 442-448.
- Abina, M. A., Lee, M. G., Descamps, V., Cordier, L., Lopez, M., Perricaudet, M., and Haddada, H. (1996). LacZ gene transfer into tumor cells abrogates tumorigenicity and protects mice against the development of further tumors. *Gene Ther.* **3**, 212-216.
- Ackerman, A. L., Kyritsis, C., Tampe, R., and Cresswell, P. (2003). Early phagosomes in dendritic cells form a cellular compartment sufficient for cross presentation of exogenous antigens. *Proc.Natl.Acad.Sci.U.S.A* **100**, 12889-12894.
- Ahn, K., Angulo, A., Ghazal, P., Peterson, P. A., Yang, Y., and Fruh, K. (1996a). Human cytomegalovirus inhibits antigen presentation by a sequential multistep process. *Proc.Natl.Acad.Sci.U.S.A* **93**, 10990-10995.
- Ahn, K., Gruhler, A., Galocha, B., Jones, T. R., Wiertz, E. J., Ploegh, H. L., Peterson, P. A., Yang, Y., and Fruh, K. (1997). The ER-luminal domain of the HCMV glycoprotein US6 inhibits peptide translocation by TAP. *Immunity*. **6**, 613-621.
- Ahn, K., Meyer, T. H., Uebel, S., Sempe, P., Djaballah, H., Yang, Y., Peterson, P. A., Fruh, K., and Tampe, R. (1996b). Molecular mechanism and species specificity of TAP inhibition by herpes simplex virus ICP47. *EMBO J.* **15**, 3247-3255.
- Aki, M., Shimbara, N., Takashina, M., Akiyama, K., Kagawa, S., Tamura, T., Tanahashi, N., Yoshimura, T., Tanaka, K., and Ichihara, A. (1994). Interferon-gamma induces different subunit organizations and functional diversity of proteasomes. *J.Biochem.(Tokyo)* **115**, 257-269.
- Alfonso, C. and Karlsson, L. (2000). Nonclassical MHC class II molecules. *Annu.Rev.Immunol.* **18**, 113-142.
- Amigorena, S., Drake, J. R., Webster, P., and Mellman, I. (1994). Transient accumulation of new class II MHC molecules in a novel endocytic compartment in B lymphocytes. *Nature* **369**, 113-120.

Androlewicz, M. J., Anderson, K. S., and Cresswell, P. (1993). Evidence that transporters associated with antigen processing translocate a major histocompatibility complex class I-binding peptide into the endoplasmic reticulum in an ATP-dependent manner. *Proc.Natl.Acad.Sci.U.S.A* **90**, 9130-9134.

Androlewicz, M. J. and Cresswell, P. (1994). Human transporters associated with antigen processing possess a promiscuous peptide-binding site. *Immunity*. **1**, 7-14.

Bakke, O. and Nordeng, T. W. (1999). Intracellular traffic to compartments for MHC class II peptide loading: signals for endosomal and polarized sorting. *Immunol.Rev.* **172**, 171-187.

Batshaw, M. L., Wilson, J. M., Raper, S., Yudkoff, M., and Robinson, M. B. (1999). Recombinant adenovirus gene transfer in adults with partial ornithine transcarbamylase deficiency (OTCD). *Hum.Gene Ther.* **10**, 2419-2437.

Biederer, C., Ries, S., Brandts, C. H., and McCormick, F. (2002). Replication-selective viruses for cancer therapy. *J.Mol.Med.* **80**, 163-175.

Blake, N., Haigh, T., Shaka'a, G., Croom-Carter, D., and Rickinson, A. (2000). The importance of exogenous antigen in priming the human CD8+ T cell response: lessons from the EBV nuclear antigen EBNA1. *J.Immunol.* **165**, 7078-7087.

Blake, N., Lee, S., Redchenko, I., Thomas, W., Steven, N., Leese, A., Steigerwald-Mullen, P., Kurilla, M. G., Frappier, L., and Rickinson, A. (1997). Human CD8+ T cell responses to EBV EBNA1: HLA class I presentation of the (Gly-Ala)-containing protein requires exogenous processing. *Immunity*. **7**, 791-802.

Bochkarev, A., Barwell, J. A., Pfuetzner, R. A., Bochkareva, E., Frappier, L., and Edwards, A. M. (1996). Crystal structure of the DNA-binding domain of the Epstein-Barr virus origin-binding protein, EBNA1, bound to DNA. *Cell* **84**, 791-800.

Braun, B. C., Glickman, M., Kraft, R., Dahlmann, B., Kloetzel, P. M., Finley, D., and Schmidt, M. (1999). The base of the proteasome regulatory particle exhibits chaperone-like activity. *Nat.Cell Biol.* **1**, 221-226.

Bushman, F. D. (2003). Targeting survival: integration site selection by retroviruses and LTR-retrotransposons. *Cell* **115**, 135-138.

Cavazzana-Calvo, M., Hacein-Bey, S., de Saint, B. G., Gross, F., Yvon, E., Nusbaum, P., Selz, F., Hue, C., Certain, S., Casanova, J. L., Bousso, P., Deist, F. L., and Fischer, A. (2000). Gene therapy of human severe combined immunodeficiency (SCID)-X1 disease. *Science* **288**, 669-672.

Introduction

Cerundolo, V., Alexander, J., Anderson, K., Lamb, C., Cresswell, P., McMichael, A., Gotch, F., and Townsend, A. (1990). Presentation of viral antigen controlled by a gene in the major histocompatibility complex. *Nature* **345**, 449-452.

Ciechanover, A. (1994). The ubiquitin-proteasome proteolytic pathway. *Cell* **79**, 13-21.

Cordier, L., Gao, G. P., Hack, A. A., McNally, E. M., Wilson, J. M., Chirmule, N., and Sweeney, H. L. (2001). Muscle-specific promoters may be necessary for adeno-associated virus-mediated gene transfer in the treatment of muscular dystrophies. *Hum. Gene Ther.* **12**, 205-215.

Coscoy, L. and Ganem, D. (2000). Kaposi's sarcoma-associated herpesvirus encodes two proteins that block cell surface display of MHC class I chains by enhancing their endocytosis. *Proc. Natl. Acad. Sci. U.S.A* **97**, 8051-8056.

Coulie, P. G., Lehmann, F., Lethe, B., Herman, J., Lurquin, C., Andrawiss, M., and Boon, T. (1995). A mutated intron sequence codes for an antigenic peptide recognized by cytolytic T lymphocytes on a human melanoma. *Proc. Natl. Acad. Sci. U.S.A* **92**, 7976-7980.

Cresswell, P. (1996). Invariant chain structure and MHC class II function. *Cell* **84**, 505-507.

Dallal, R. M. and Lotze, M. T. (2001). Immunotherapy of metastasis. *Surg. Oncol. Clin. N. Am.* **10**, 433-47, xi.

Denzin, L. K. and Cresswell, P. (1995). HLA-DM induces CLIP dissociation from MHC class II alpha beta dimers and facilitates peptide loading. *Cell* **82**, 155-165.

DeWeese, T. L., van der, P. H., Li, S., Mikhak, B., Drew, R., Goemann, M., Hamper, U., DeJong, R., Detorie, N., Rodriguez, R., Haulk, T., DeMarzo, A. M., Piantadosi, S., Yu, D. C., Chen, Y., Henderson, D. R., Carducci, M. A., Nelson, W. G., and Simons, J. W. (2001). A phase I trial of CV706, a replication-competent, PSA selective oncolytic adenovirus, for the treatment of locally recurrent prostate cancer following radiation therapy. *Cancer Res.* **61**, 7464-7472.

Eleuteri, A. M., Kohanski, R. A., Cardozo, C., and Orłowski, M. (1997). Bovine spleen multicatalytic proteinase complex (proteasome). Replacement of X, Y, and Z subunits by LMP7, LMP2, and MECL1 and changes in properties and specificity. *J. Biol. Chem.* **272**, 11824-11831.

Esquivel, F., Yewdell, J., and Bennink, J. (1992). RMA/S cells present endogenously synthesized cytosolic proteins to class I-restricted cytotoxic T lymphocytes. *J. Exp. Med.* **175**, 163-168.

- Etoh, T., Himeno, Y., Matsumoto, T., Aramaki, M., Kawano, K., Nishizono, A., and Kitano, S. (2003). Oncolytic viral therapy for human pancreatic cancer cells by reovirus. *Clin.Cancer Res.* **9**, 1218-1223.
- Ferrell, K., Wilkinson, C. R., Dubiel, W., and Gordon, C. (2000). Regulatory subunit interactions of the 26S proteasome, a complex problem. *Trends Biochem.Sci.* **25**, 83-88.
- Fetten, J. V., Roy, N., and Gilboa, E. (1991). A frameshift mutation at the NH2 terminus of the nucleoprotein gene does not affect generation of cytotoxic T lymphocyte epitopes. *J.Immunol.* **147**, 2697-2705.
- Furman, M. H., Dey, N., Tortorella, D., and Ploegh, H. L. (2002). The human cytomegalovirus US10 gene product delays trafficking of major histocompatibility complex class I molecules. *J.Virol.* **76**, 11753-11756.
- Gambotto, A., Dworacki, G., Cicinnati, V., Kenniston, T., Steitz, J., Tuting, T., Robbins, P. D., and DeLeo, A. B. (2000). Immunogenicity of enhanced green fluorescent protein (EGFP) in BALB/c mice: identification of an H2-Kd-restricted CTL epitope. *Gene Ther.* **7**, 2036-2040.
- Gilbert, M. J., Riddell, S. R., Plachter, B., and Greenberg, P. D. (1996). Cytomegalovirus selectively blocks antigen processing and presentation of its immediate-early gene product. *Nature* **383**, 720-722.
- Glickman, M. H. and Ciechanover, A. (2002). The ubiquitin-proteasome proteolytic pathway: destruction for the sake of construction. *Physiol Rev.* **82**, 373-428.
- Gottesman, M. M. (2003). Cancer gene therapy: an awkward adolescence. *Cancer Gene Ther.* **10**, 501-508.
- Greenberg, M. E., Iafrate, A. J., and Skowronski, J. (1998). The SH3 domain-binding surface and an acidic motif in HIV-1 Nef regulate trafficking of class I MHC complexes. *EMBO J.* **17**, 2777-2789.
- Griffin, J. P., Chu, R., and Harding, C. V. (1997). Early endosomes and a late endocytic compartment generate different peptide-class II MHC complexes via distinct processing mechanisms. *J.Immunol.* **158**, 1523-1532.
- Groll, M., Bajorek, M., Kohler, A., Moroder, L., Rubin, D. M., Huber, R., Glickman, M. H., and Finley, D. (2000). A gated channel into the proteasome core particle. *Nat.Struct.Biol.* **7**, 1062-1067.

Introduction

Groll, M., Ditzel, L., Lowe, J., Stock, D., Bochtler, M., Bartunik, H. D., and Huber, R. (1997). Structure of 20S proteasome from yeast at 2.4 Å resolution. *Nature* **386**, 463-471.

Guagliardi, L. E., Koppelman, B., Blum, J. S., Marks, M. S., Cresswell, P., and Brodsky, F. M. (1990). Co-localization of molecules involved in antigen processing and presentation in an early endocytic compartment. *Nature* **343**, 133-139.

Guermonprez, P., Saveanu, L., Kleijmeer, M., Davoust, J., Van Endert, P., and Amigorena, S. (2003). ER-phagosome fusion defines an MHC class I cross-presentation compartment in dendritic cells. *Nature* **425**, 397-402.

Guermonprez, P., Valladeau, J., Zitvogel, L., Thery, C., and Amigorena, S. (2002). Antigen presentation and T cell stimulation by dendritic cells. *Annu.Rev.Immunol.* **20**, 621-667.

Guilloux, Y., Lucas, S., Brichard, V. G., Van Pel, A., Viret, C., De Plaen, E., Brasseur, F., Lethe, B., Jotereau, F., and Boon, T. (1996). A peptide recognized by human cytolytic T lymphocytes on HLA-A2 melanomas is encoded by an intron sequence of the N-acetylglucosaminyltransferase V gene. *J.Exp.Med.* **183**, 1173-1183.

Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., Le Deist, F., Wulffraat, N., McIntyre, E., Radford, I., Villeval, J. L., Fraser, C. C., Cavazzana-Calvo, M., and Fischer, A. (2003a). A serious adverse event after successful gene therapy for X-linked severe combined immunodeficiency. *N.Engl.J.Med.* **348**, 255-256.

Hacein-Bey-Abina, S., Von Kalle, C., Schmidt, M., McCormack, M. P., Wulffraat, N., Leboulch, P., Lim, A., Osborne, C. S., Pawliuk, R., Morillon, E., Sorensen, R., Forster, A., Fraser, P., Cohen, J. I., de Saint, B. G., Alexander, I., Wintergerst, U., Frebourg, T., Aurias, A., Stoppa-Lyonnet, D., Romana, S., Radford-Weiss, I., Gross, F., Valensi, F., Delabesse, E., Macintyre, E., Sigaux, F., Soulier, J., Leiva, L. E., Wissler, M., Prinz, C., Rabbitts, T. H., Le Deist, F., Fischer, A., and Cavazzana-Calvo, M. (2003b). LMO2-associated clonal T cell proliferation in two patients after gene therapy for SCID-X1. *Science* **302**, 415-419.

Harding, C. V., Roof, R. W., and Unanue, E. R. (1989). Turnover of Ia-peptide complexes is facilitated in viable antigen-presenting cells: biosynthetic turnover of Ia vs. peptide exchange. *Proc.Natl.Acad.Sci.U.S.A* **86**, 4230-4234.

Heath, W. R. and Carbone, F. R. (2001). Cross-presentation, dendritic cells, tolerance and immunity. *Annu.Rev.Immunol.* **19**, 47-64.

Heise, C. C., Williams, A., Olesch, J., and Kirn, D. H. (1999). Efficacy of a replication-competent adenovirus (ONYX-015) following intratumoral injection: intratumoral spread and distribution effects. *Cancer Gene Ther.* **6**, 499-504.

- Hendil, K. B., Khan, S., and Tanaka, K. (1998). Simultaneous binding of PA28 and PA700 activators to 20 S proteasomes. *Biochem.J.* **332** (Pt 3), 749-754.
- Hengel, H., Koopmann, J. O., Flohr, T., Muranyi, W., Goulmy, E., Hammerling, G. J., Koszinowski, U. H., and Momburg, F. (1997). A viral ER-resident glycoprotein inactivates the MHC-encoded peptide transporter. *Immunity.* **6**, 623-632.
- Hewitt, E. W., Gupta, S. S., and Lehner, P. J. (2001). The human cytomegalovirus gene product US6 inhibits ATP binding by TAP. *EMBO J.* **20**, 387-396.
- Hiltbold, E. M. and Roche, P. A. (2002). Trafficking of MHC class II molecules in the late secretory pathway. *Curr.Opin.Immunol.* **14**, 30-35.
- Hochstrasser, M. (1996). Ubiquitin-dependent protein degradation. *Annu.Rev.Genet.* **30**, 405-439.
- Horio, Y., Hasegawa, Y., Sekido, Y., Takahashi, M., Roth, J. A., and Shimokata, K. (2000). Synergistic effects of adenovirus expressing wild-type p53 on chemosensitivity of non-small cell lung cancer cells. *Cancer Gene Ther.* **7**, 537-544.
- Horwitz, M. S. (1996). "Adenoviruses. in *Fields Virology*." Lippincott-Raven, Philadelphia, Pennsylvania.
- Houde, M., Bertholet, S., Gagnon, E., Brunet, S., Goyette, G., Laplante, A., Princiotta, M. F., Thibault, P., Sacks, D., and Desjardins, M. (2003). Phagosomes are competent organelles for antigen cross-presentation. *Nature* **425**, 402-406.
- Huang, A. Y., Golumbek, P., Ahmadzadeh, M., Jaffee, E., Pardoll, D., and Levitsky, H. (1994). Role of bone marrow-derived cells in presenting MHC class I-restricted tumor antigens. *Science* **264**, 961-965.
- Hudson, A. W., Howley, P. M., and Ploegh, H. L. (2001). A human herpesvirus 7 glycoprotein, U21, diverts major histocompatibility complex class I molecules to lysosomes. *J.Virol.* **75**, 12347-12358.
- Ishido, S., Wang, C., Lee, B. S., Cohen, G. B., and Jung, J. U. (2000). Downregulation of major histocompatibility complex class I molecules by Kaposi's sarcoma-associated herpesvirus K3 and K5 proteins. *J.Virol.* **74**, 5300-5309.
- Jooss, K., Yang, Y., Fisher, K. J., and Wilson, J. M. (1998). Transduction of dendritic cells by DNA viral vectors directs the immune response to transgene products in muscle fibers. *J.Virol.* **72**, 4212-4223.

Introduction

Juillard, V., Villefroy, P., Godfrin, D., Pavirani, A., Venet, A., and Guillet, J. G. (1995). Long-term humoral and cellular immunity induced by a single immunization with replication-defective adenovirus recombinant vector. *Eur.J.Immunol.* **25**, 3467-3473.

Jung, D., Jaeger, E., Cayeux, S., Blankenstein, T., Hilmes, C., Karbach, J., Moebius, U., Knuth, A., Huber, C., and Seliger, B. (1998). Strong immunogenic potential of a B7 retroviral expression vector: generation of HLA-B7-restricted CTL response against selectable marker genes. *Hum.Gene Ther.* **9**, 53-62.

Khan, S., de Giuli, R., Schmidtke, G., Bruns, M., Buchmeier, M., van den, B. M., and Groettrup, M. (2001). Cutting edge: neosynthesis is required for the presentation of a T cell epitope from a long-lived viral protein. *J.Immunol.* **167**, 4801-4804.

Kilani, R. T., Tamimi, Y., Hanel, E. G., Wong, K. K., Karmali, S., Lee, P. W., and Moore, R. B. (2003). Selective reovirus killing of bladder cancer in a co-culture spheroid model. *Virus Res.* **93**, 1-12.

Klein, G. (1994). Epstein-Barr virus strategy in normal and neoplastic B cells. *Cell* **77**, 791-793.

Kurts, C., Heath, W. R., Carbone, F. R., Allison, J., Miller, J. F., and Kosaka, H. (1996). Constitutive class I-restricted exogenous presentation of self antigens in vivo. *J.Exp.Med.* **184**, 923-930.

Kyritsis, C., Gorbulev, S., Hutschenreiter, S., Pawlitschko, K., Abele, R., and Tampe, R. (2001). Molecular mechanism and structural aspects of transporter associated with antigen processing inhibition by the cytomegalovirus protein US6. *J.Biol.Chem.* **276**, 48031-48039.

Latta-Mahieu, M., Rolland, M., Caillet, C., Wang, M., Kennel, P., Mahfouz, I., Loquet, I., Dedieu, J. F., Mahfoudi, A., Trannoy, E., and Thuillier, V. (2002). Gene transfer of a chimeric trans-activator is immunogenic and results in short-lived transgene expression. *Hum.Gene Ther.* **13**, 1611-1620.

Le Gall, S., Buseyne, F., Trocha, A., Walker, B. D., Heard, J. M., and Schwartz, O. (2000). Distinct trafficking pathways mediate Nef-induced and clathrin-dependent major histocompatibility complex class I down-regulation. *J.Virol.* **74**, 9256-9266.

Lee, M. A., Diamond, M. E., and Yates, J. L. (1999). Genetic evidence that EBNA-1 is needed for efficient, stable latent infection by Epstein-Barr virus. *J.Virol.* **73**, 2974-2982.

Lee, S. P., Brooks, J. M., Al Jarrah, H., Thomas, W. A., Haigh, T. A., Taylor, G. S., Humme, S., Schepers, A., Hammerschmidt, W., Yates, J. L., Rickinson, A. B., and Blake, N. W.

(2004). CD8 T cell recognition of endogenously expressed epstein-barr virus nuclear antigen 1. *J.Exp.Med.* **199**, 1409-1420.

Lehner, P. J., Karttunen, J. T., Wilkinson, G. W., and Cresswell, P. (1997). The human cytomegalovirus US6 glycoprotein inhibits transporter associated with antigen processing-dependent peptide translocation. *Proc.Natl.Acad.Sci.U.S.A* **94**, 6904-6909.

Levitskaya, J., Coram, M., Levitsky, V., Imreh, S., Steigerwald-Mullen, P. M., Klein, G., Kurilla, M. G., and Masucci, M. G. (1995). Inhibition of antigen processing by the internal repeat region of the Epstein-Barr virus nuclear antigen-1. *Nature* **375**, 685-688.

Levitskaya, J., Sharipo, A., Leonchiks, A., Ciechanover, A., and Masucci, M. G. (1997). Inhibition of ubiquitin/proteasome-dependent protein degradation by the Gly-Ala repeat domain of the Epstein-Barr virus nuclear antigen 1. *Proc.Natl.Acad.Sci.U.S.A* **94**, 12616-12621.

Lindner, R. and Unanue, E. R. (1996). Distinct antigen MHC class II complexes generated by separate processing pathways. *EMBO J.* **15**, 6910-6920.

Lizee, G., Basha, G., and Jefferies, W. A. (2005). Tails of wonder: endocytic-sorting motifs key for exogenous antigen presentation. *Trends Immunol.* **26**, 141-149.

Lizee, G., Basha, G., Tiong, J., Julien, J. P., Tian, M., Biron, K. E., and Jefferies, W. A. (2003). Control of dendritic cell cross-presentation by the major histocompatibility complex class I cytoplasmic domain. *Nat.Immunol.* **4**, 1065-1073.

Lorenzo, M. E., Jung, J. U., and Ploegh, H. L. (2002). Kaposi's sarcoma-associated herpesvirus K3 utilizes the ubiquitin-proteasome system in routing class major histocompatibility complexes to late endocytic compartments. *J.Virol.* **76**, 5522-5531.

Lotteau, V., Teyton, L., Peleraux, A., Nilsson, T., Karlsson, L., Schmid, S. L., Quaranta, V., and Peterson, P. A. (1990). Intracellular transport of class II MHC molecules directed by invariant chain. *Nature* **348**, 600-605.

Lupetti, R., Pisarra, P., Verrecchia, A., Farina, C., Nicolini, G., Anichini, A., Bordignon, C., Sensi, M., Parmiani, G., and Traversari, C. (1998). Translation of a retained intron in tyrosinase-related protein (TRP) 2 mRNA generates a new cytotoxic T lymphocyte (CTL)-defined and shared human melanoma antigen not expressed in normal cells of the melanocytic lineage. *J.Exp.Med.* **188**, 1005-1016.

Introduction

Macagno, A., Gilliet, M., Sallusto, F., Lanzavecchia, A., Nestle, F. O., and Groettrup, M. (1999). Dendritic cells up-regulate immunoproteasomes and the proteasome regulator PA28 during maturation. *Eur.J.Immunol.* **29**, 4037-4042.

Malarkannan, S., Afkarian, M., and Shastri, N. (1995). A rare cryptic translation product is presented by Kb major histocompatibility complex class I molecule to alloreactive T cells. *J.Exp.Med.* **182**, 1739-1750.

Martiniello-Wilks, R., Tsatralis, T., Russell, P., Brookes, D. E., Zandvliet, D., Lockett, L. J., Both, G. W., Molloy, P. L., and Russell, P. J. (2002). Transcription-targeted gene therapy for androgen-independent prostate cancer. *Cancer Gene Ther.* **9**, 443-452.

Mayrand, S. M. and Green, W. R. (1998). Non-traditionally derived CTL epitopes: exceptions that prove the rules? *Immunol.Today* **19**, 551-556.

Mayrand, S. M., Schwarz, D. A., and Green, W. R. (1998). An alternative translational reading frame encodes an immunodominant retroviral CTL determinant expressed by an immunodeficiency-causing retrovirus. *J.Immunol.* **160**, 39-50.

Mitchell, R. S., Beitzel, B. F., Schroder, A. R., Shinn, P., Chen, H., Berry, C. C., Ecker, J. R., and Bushman, F. D. (2004). Retroviral DNA integration: ASLV, HIV, and MLV show distinct target site preferences. *PLoS.Biol.* **2**, E234.

Monaco, J. J. (1992). A molecular model of MHC class-I-restricted antigen processing. *Immunol.Today* **13**, 173-179.

Morris, J. C., Conerly, M., Thomasson, B., Storek, J., Riddell, S. R., and Kiem, H. P. (2004). Induction of cytotoxic T-lymphocyte responses to enhanced green and yellow fluorescent proteins after myeloablative conditioning. *Blood* **103**, 492-499.

Neefjes, J. J., Momburg, F., and Hammerling, G. J. (1993). Selective and ATP-dependent translocation of peptides by the MHC-encoded transporter. *Science* **261**, 769-771.

Norman, K. L., Hirasawa, K., Yang, A. D., Shields, M. A., and Lee, P. W. (2004). Reovirus oncolysis: the Ras/RalGEF/p38 pathway dictates host cell permissiveness to reovirus infection. *Proc.Natl.Acad.Sci.U.S.A* **101**, 11099-11104.

Odorizzi, C. G., Trowbridge, I. S., Xue, L., Hopkins, C. R., Davis, C. D., and Collawn, J. F. (1994). Sorting signals in the MHC class II invariant chain cytoplasmic tail and transmembrane region determine trafficking to an endocytic processing compartment. *J.Cell Biol.* **126**, 317-330.

- Ossevoort, M., Visser, B. M., van den Wollenberg, D. J., van der Voort, E. I., Offringa, R., Melief, C. J., Toes, R. E., and Hoeben, R. C. (2003). Creation of immune 'stealth' genes for gene therapy through fusion with the Gly-Ala repeat of EBNA-1. *Gene Ther.* **10**, 2020-2028.
- Paabo, S., Severinsson, L., Andersson, M., Martens, I., Nilsson, T., and Peterson, P. A. (1989). Adenovirus proteins and MHC expression. *Adv.Cancer Res.* **52**, 151-163.
- Pamer, E. and Cresswell, P. (1998). Mechanisms of MHC class I--restricted antigen processing. *Annu.Rev.Immunol.* **16**, 323-358.
- Pecora, A. L., Rizvi, N., Cohen, G. I., Meropol, N. J., Stermann, D., Marshall, J. L., Goldberg, S., Gross, P., O'Neil, J. D., Groene, W. S., Roberts, M. S., Rabin, H., Bamat, M. K., and Lorence, R. M. (2002). Phase I trial of intravenous administration of PV701, an oncolytic virus, in patients with advanced solid cancers. *J.Clin.Oncol.* **20**, 2251-2266.
- Peters, J. M., Franke, W. W., and Kleinschmidt, J. A. (1994). Distinct 19 S and 20 S subcomplexes of the 26 S proteasome and their distribution in the nucleus and the cytoplasm. *J.Biol.Chem.* **269**, 7709-7718.
- Peters, P. J., Neefjes, J. J., Oorschot, V., Ploegh, H. L., and Geuze, H. J. (1991). Segregation of MHC class II molecules from MHC class I molecules in the Golgi complex for transport to lysosomal compartments. *Nature* **349**, 669-676.
- Probst-Kepper, M., Stroobant, V., Kridel, R., Gaugler, B., Landry, C., Brasseur, F., Cosyns, J. P., Weynand, B., Boon, T., and Van Den Eynde, B. J. (2001). An alternative open reading frame of the human macrophage colony-stimulating factor gene is independently translated and codes for an antigenic peptide of 14 amino acids recognized by tumor-infiltrating CD8 T lymphocytes. *J.Exp.Med.* **193**, 1189-1198.
- Reits, E. A., Vos, J. C., Gromme, M., and Neefjes, J. (2000). The major substrates for TAP in vivo are derived from newly synthesized proteins. *Nature* **404**, 774-778.
- Reyes-Sandoval, A. and Ertl, H. C. (2001). DNA vaccines. *Curr.Mol.Med.* **1**, 217-243.
- Rickinson, A. B. and Moss, D. J. (1997). Human cytotoxic T lymphocyte responses to Epstein-Barr virus infection. *Annu.Rev.Immunol.* **15**, 405-431.
- Robbins, P. F., El Gamil, M., Li, Y. F., Fitzgerald, E. B., Kawakami, Y., and Rosenberg, S. A. (1997). The intronic region of an incompletely spliced gp100 gene transcript encodes an epitope recognized by melanoma-reactive tumor-infiltrating lymphocytes. *J.Immunol.* **159**, 303-308.

Introduction

Roche, P. A. and Cresswell, P. (1990). Invariant chain association with HLA-DR molecules inhibits immunogenic peptide binding. *Nature* **345**, 615-618.

Ronsin, C., Chung-Scott, V., Poullion, I., Aknouche, N., Gaudin, C., and Triebel, F. (1999). A non-AUG-defined alternative open reading frame of the intestinal carboxyl esterase mRNA generates an epitope recognized by renal cell carcinoma-reactive tumor-infiltrating lymphocytes in situ. *J.Immunol.* **163**, 483-490.

Rowe, M., Lear, A. L., Croom-Carter, D., Davies, A. H., and Rickinson, A. B. (1992). Three pathways of Epstein-Barr virus gene activation from EBNA1-positive latency in B lymphocytes. *J.Virol.* **66**, 122-131.

Salter, R. D. and Cresswell, P. (1986). Impaired assembly and transport of HLA-A and -B antigens in a mutant TxB cell hybrid. *EMBO J.* **5**, 943-949.

Schroder, A. R., Shinn, P., Chen, H., Berry, C., Ecker, J. R., and Bushman, F. (2002). HIV-1 integration in the human genome favors active genes and local hotspots. *Cell* **110**, 521-529.

Schubert, U., Anton, L. C., Gibbs, J., Norbury, C. C., Yewdell, J. W., and Bennink, J. R. (2000). Rapid degradation of a large fraction of newly synthesized proteins by proteasomes. *Nature* **404**, 770-774.

Schumacher, T. N., Kantesaria, D. V., Serreze, D. V., Roopenian, D. C., and Ploegh, H. L. (1994). Transporters from H-2b, H-2d, H-2s, H-2k, and H-2g7 (NOD/Lt) haplotype translocate similar sets of peptides. *Proc.Natl.Acad.Sci.U.S.A* **91**, 13004-13008.

Schwab, S. R., Li, K. C., Kang, C., and Shastri, N. (2003). Constitutive display of cryptic translation products by MHC class I molecules. *Science* **301**, 1367-1371.

Schwartz, O., Marechal, V., Le Gall, S., Lemonnier, F., and Heard, J. M. (1996). Endocytosis of major histocompatibility complex class I molecules is induced by the HIV-1 Nef protein. *Nat.Med.* **2**, 338-342.

Schwarz, K., Eggers, M., Soza, A., Koszinowski, U. H., Kloetzel, P. M., and Groettrup, M. (2000). The proteasome regulator PA28alpha/beta can enhance antigen presentation without affecting 20S proteasome subunit composition. *Eur.J.Immunol.* **30**, 3672-3679.

Shah, A. C., Benos, D., Gillespie, G. Y., and Markert, J. M. (2003). Oncolytic viruses: clinical applications as vectors for the treatment of malignant gliomas. *J.Neurooncol.* **65**, 203-226.

- Shah, W. A., Ambinder, R. F., Hayward, G. S., and Hayward, S. D. (1992). Binding of EBNA-1 to DNA creates a protease-resistant domain that encompasses the DNA recognition and dimerization functions. *J.Virol.* **66**, 3355-3362.
- Sharipo, A., Imreh, M., Leonchiks, A., Branden, C., and Masucci, M. G. (2001). cis-Inhibition of proteasomal degradation by viral repeats: impact of length and amino acid composition. *FEBS Lett.* **499**, 137-142.
- Shastri, N., Nguyen, V., and Gonzalez, F. (1995). Major histocompatibility class I molecules can present cryptic translation products to T-cells. *J.Biol.Chem.* **270**, 1088-1091.
- Shepherd, J. C., Schumacher, T. N., Ashton-Rickardt, P. G., Imaeda, S., Ploegh, H. L., Janeway, C. A., Jr., and Tonegawa, S. (1993). TAP1-dependent peptide translocation in vitro is ATP dependent and peptide selective. *Cell* **74**, 577-584.
- Sherman, M. A., Weber, D. A., and Jensen, P. E. (1995). DM enhances peptide binding to class II MHC by release of invariant chain-derived peptide. *Immunity.* **3**, 197-205.
- Sigal, L. J., Crotty, S., Andino, R., and Rock, K. L. (1999). Cytotoxic T-cell immunity to virus-infected non-haematopoietic cells requires presentation of exogenous antigen. *Nature* **398**, 77-80.
- Sijts, A. J., Ruppert, T., Rehmann, B., Schmidt, M., Koszinowski, U., and Kloetzel, P. M. (2000a). Efficient generation of a hepatitis B virus cytotoxic T lymphocyte epitope requires the structural features of immunoproteasomes. *J.Exp.Med.* **191**, 503-514.
- Sijts, A. J., Standera, S., Toes, R. E., Ruppert, T., Beekman, N. J., van Veelen, P. A., Ossendorp, F. A., Melief, C. J., and Kloetzel, P. M. (2000b). MHC class I antigen processing of an adenovirus CTL epitope is linked to the levels of immunoproteasomes in infected cells. *J.Immunol.* **164**, 4500-4506.
- Stohwasser, R., Standera, S., Peters, I., Kloetzel, P. M., and Groettrup, M. (1997). Molecular cloning of the mouse proteasome subunits MC14 and MECL-1: reciprocally regulated tissue expression of interferon-gamma-modulated proteasome subunits. *Eur.J.Immunol.* **27**, 1182-1187.
- Strickland, E., Hakala, K., Thomas, P. J., and DeMartino, G. N. (2000). Recognition of misfolding proteins by PA700, the regulatory subcomplex of the 26 S proteasome. *J.Biol.Chem.* **275**, 5565-5572.
- Svensson, M. and Wick, M. J. (1999). Classical MHC class I peptide presentation of a bacterial fusion protein by bone marrow-derived dendritic cells. *Eur.J.Immunol.* **29**, 180-188.

Introduction

Tellam, J., Connolly, G., Green, K. J., Miles, J. J., Moss, D. J., Burrows, S. R., and Khanna, R. (2004). Endogenous presentation of CD8+ T cell epitopes from Epstein-Barr virus-encoded nuclear antigen 1. *J.Exp.Med.* **199**, 1421-1431.

Thomis, D. C., Marktel, S., Bonini, C., Traversari, C., Gilman, M., Bordignon, C., and Clackson, T. (2001). A Fas-based suicide switch in human T cells for the treatment of graft-versus-host disease. *Blood* **97**, 1249-1257.

Tomazin, R., Hill, A. B., Jugovic, P., York, I., Van Endert, P., Ploegh, H. L., Andrews, D. W., and Johnson, D. C. (1996). Stable binding of the herpes simplex virus ICP47 protein to the peptide binding site of TAP. *EMBO J.* **15**, 3256-3266.

Tortorella, D., Gewurz, B. E., Furman, M. H., Schust, D. J., and Ploegh, H. L. (2000). Viral subversion of the immune system. *Annu.Rev.Immunol.* **18**, 861-926.

Townsend, A. and Bodmer, H. (1989). Antigen recognition by class I-restricted T lymphocytes. *Annu.Rev.Immunol.* **7**, 601-624.

Tripathy, S. K., Black, H. B., Goldwasser, E., and Leiden, J. M. (1996). Immune responses to transgene-encoded proteins limit the stability of gene expression after injection of replication-defective adenovirus vectors. *Nat.Med.* **2**, 545-550.

Uebel, S., Kraas, W., Kienle, S., Wiesmuller, K. H., Jung, G., and Tampe, R. (1997). Recognition principle of the TAP transporter disclosed by combinatorial peptide libraries. *Proc.Natl.Acad.Sci.U.S.A* **94**, 8976-8981.

Van Den Eynde, B. J., Gaugler, B., Probst-Kepper, M., Michaux, L., Devuyst, O., Lorge, F., Weynants, P., and Boon, T. (1999). A new antigen recognized by cytolytic T lymphocytes on a human kidney tumor results from reverse strand transcription. *J.Exp.Med.* **190**, 1793-1800.

van Hall, T., Sijts, A., Camps, M., Offringa, R., Melief, C., Kloetzel, P. M., and Ossendorp, F. (2000). Differential influence on cytotoxic T lymphocyte epitope presentation by controlled expression of either proteasome immunosubunits or PA28. *J.Exp.Med.* **192**, 483-494.

Villadangos, J. A., Bryant, R. A., Deussing, J., Driessen, C., Lennon-Dumenil, A. M., Riese, R. J., Roth, W., Saftig, P., Shi, G. P., Chapman, H. A., Peters, C., and Ploegh, H. L. (1999). Proteases involved in MHC class II antigen presentation. *Immunol.Rev.* **172**, 109-120.

Voges, D., Zwickl, P., and Baumeister, W. (1999). The 26S proteasome: a molecular machine designed for controlled proteolysis. *Annu.Rev.Biochem.* **68**, 1015-1068.

Voo, K. S., Fu, T., Wang, H. Y., Tellam, J., Heslop, H. E., Brenner, M. K., Rooney, C. M., and Wang, R. F. (2004). Evidence for the presentation of major histocompatibility complex class I-restricted Epstein-Barr virus nuclear antigen 1 peptides to CD8⁺ T lymphocytes. *J.Exp.Med.* **199**, 459-470.

Wang, R. F., Johnston, S. L., Zeng, G., Topalian, S. L., Schwartzentruber, D. J., and Rosenberg, S. A. (1998). A breast and melanoma-shared tumor antigen: T cell responses to antigenic peptides translated from different open reading frames. *J.Immunol.* **161**, 3598-3606.

Wang, R. F., Parkhurst, M. R., Kawakami, Y., Robbins, P. F., and Rosenberg, S. A. (1996). Utilization of an alternative open reading frame of a normal gene in generating a novel human cancer antigen. *J.Exp.Med.* **183**, 1131-1140.

Watts, C. (1997). Capture and processing of exogenous antigens for presentation on MHC molecules. *Annu.Rev.Immunol.* **15**, 821-850.

Wesseling, J. G., Yamamoto, M., Adachi, Y., Bosma, P. J., van Wijland, M., Blackwell, J. L., Li, H., Reynolds, P. N., Dmitriev, I., Vickers, S. M., Huibregtse, K., and Curiel, D. T. (2001). Midkine and cyclooxygenase-2 promoters are promising for adenoviral vector gene delivery of pancreatic carcinoma. *Cancer Gene Ther.* **8**, 990-996.

Wiertz, E. J., Jones, T. R., Sun, L., Bogoy, M., Geuze, H. J., and Ploegh, H. L. (1996a). The human cytomegalovirus US11 gene product dislocates MHC class I heavy chains from the endoplasmic reticulum to the cytosol. *Cell* **84**, 769-779.

Wiertz, E. J., Tortorella, D., Bogoy, M., Yu, J., Mothes, W., Jones, T. R., Rapoport, T. A., and Ploegh, H. L. (1996b). Sec61-mediated transfer of a membrane protein from the endoplasmic reticulum to the proteasome for destruction. *Nature* **384**, 432-438.

Wiley website (2005). www.wiley.co.uk/genmed/clinical. *J.Gene Med.*

Williams, D. B., Barber, B. H., Flavell, R. A., and Allen, H. (1989). Role of beta 2-microglobulin in the intracellular transport and surface expression of murine class I histocompatibility molecules. *J.Immunol.* **142**, 2796-2806.

Yang, Y., Jooss, K. U., Su, Q., Ertl, H. C., and Wilson, J. M. (1996a). Immune responses to viral antigens versus transgene product in the elimination of recombinant adenovirus-infected hepatocytes in vivo. *Gene Ther.* **3**, 137-144.

Yang, Y., Su, Q., and Wilson, J. M. (1996b). Role of viral antigens in destructive cellular immune responses to adenovirus vector-transduced cells in mouse lungs. *J.Virol.* **70**, 7209-7212.

Introduction

Yates, J. L., Warren, N., and Sugden, B. (1985). Stable replication of plasmids derived from Epstein-Barr virus in various mammalian cells. *Nature* **313**, 812-815.

Yen, N., Ioannides, C. G., Xu, K., Swisher, S. G., Lawrence, D. D., Kemp, B. L., El Naggar, A. K., Cristiano, R. J., Fang, B., Glisson, B. S., Hong, W. K., Khuri, F. R., Kurie, J. M., Lee, J. J., Lee, J. S., Merritt, J. A., Mukhopadhyay, T., Nesbitt, J. C., Nguyen, D., Perez-Soler, R., Pisters, K. M., Putnam, J. B., Jr., Schrump, D. S., Shin, D. M., Walsh, G. L., and Roth, J. A. (2000). Cellular and humoral immune responses to adenovirus and p53 protein antigens in patients following intratumoral injection of an adenovirus vector expressing wild-type. P53 (Ad-p53). *Cancer Gene Ther.* **7**, 530-536.

Yewdell, J. W., Anton, L. C., and Bennink, J. R. (1996). Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? *J.Immunol.* **157**, 1823-1826.

Yewdell, J. W. and Bennink, J. R. (1992). Cell biology of antigen processing and presentation to major histocompatibility complex class I molecule-restricted T lymphocytes. *Adv.Immunol.* **52**, 1-123.

Yewdell, J. W., Norbury, C. C., and Bennink, J. R. (1999). Mechanisms of exogenous antigen presentation by MHC class I molecules in vitro and in vivo: implications for generating CD8+ T cell responses to infectious agents, tumors, transplants, and vaccines. *Adv.Immunol.* **73**, 1-77.

Yewdell, J. W., Reits, E., and Neefjes, J. (2003). Making sense of mass destruction: quantitating MHC class I antigen presentation. *Nat.Rev.Immunol.* **3**, 952-961.

Yoon, T. K., Shichinohe, T., Laquerre, S., and Kasahara, N. (2001). Selectively replicating adenoviruses for oncolytic therapy. *Curr.Cancer Drug Targets.* **1**, 85-107.

Yoshida, Y., Tomizawa, M., Bahar, R., Miyauchi, M., Yamaguchi, T., Saisho, H., Kadomatsu, K., Muramatsu, T., Matsubara, S., Sakiyama, S., and Tagawa, M. (2002). A promoter region of midkine gene can activate transcription of an exogenous suicide gene in human pancreatic cancer. *Anticancer Res.* **22**, 117-120.

Ziegler, H., Thale, R., Lucin, P., Muranyi, W., Flohr, T., Hengel, H., Farrell, H., Rawlinson, W., and Koszinowski, U. H. (1997). A mouse cytomegalovirus glycoprotein retains MHC class I complexes in the ERGIC/cis-Golgi compartments. *Immunity.* **6**, 57-66.

Zijlstra, M., Bix, M., Simister, N. E., Loring, J. M., Raulet, D. H., and Jaenisch, R. (1990). Beta 2-microglobulin deficient mice lack CD4-8+ cytolytic T cells. *Nature* **344**, 742-746.

Introduction